Endpoints News 2026年3月9日 GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront
Endpoints News 2026年3月7日 UniQure’s dispute with FDA; Zealand’s obesity readout; China takes on world’s most expensive medicines; and more
Endpoints News 2026年3月6日 Pfizer gets obesity drug approval in China shortly after buying local rights
Endpoints News 2026年3月6日 Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News 2026年3月5日 Helus Pharma's stock slides after psychedelic drug data face questions over dosing